PMID- 16104372
OWN - NLM
STAT- MEDLINE
DCOM- 20050915
LR  - 20161124
IS  - 0743-6661 (Print)
IS  - 0743-6661 (Linking)
VI  - 32
IP  - 4
DP  - 2000
TI  - Mortality in two recent reports of clinical trials on patients with congestive 
      heart failure compared with mortality in three previous clinical trials.
PG  - 254-61
AB  - BACKGROUND: Several clinical trials of drug treatment of patients with congestive 
      heart failure (CHF) have previously been reported as Mortality Abstracts in the 
      Journal of Insurance Medicine. Results are presented here for two similar 
      clinical trials reported in September 1999 and compared with the previous 
      results. RESULTS: In a recent international multicenter clinical trial, excess 
      mortality in terms of excess death rates (EDRs) was reduced from 195 per 1000 per 
      year in the placebo group to 139 in the group treated with Spironolactone. There 
      was no significant reduction in the Danish multicenter study of Dofetilide to 
      convert the atrial fibrillation (AF) to a normal rhythm in the 25% of the CHF 
      patients who had AF (EDR was 224 in the placebo group and 216 in the Dofetilide 
      group). In both of these studies, there were more patients with severe CHF than 
      in the previous studies and the EDR values were higher. Results from the Danish 
      study by severity according to the New York Heart Association (NYHA) 
      classification show a progressive increase in EDR from 173 in class 2 to 237 in 
      class 3 to 392 in class 4. CONCLUSION: Excess mortality in symptomatic CHF is far 
      outside the issue limits for individual life insurance, but these results are of 
      potential utility for the underwriting of such cases for structured settlement 
      annuities.
FAU - Singer, R B
AU  - Singer RB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Insur Med
JT  - Journal of insurance medicine (New York, N.Y.)
JID - 8401468
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Diuretics)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 0 (Phenethylamines)
RN  - 0 (Placebos)
RN  - 0 (Sulfonamides)
RN  - 27O7W4T232 (Spironolactone)
RN  - R4Z9X1N2ND (dofetilide)
MH  - Aged
MH  - Anti-Arrhythmia Agents/therapeutic use
MH  - *Clinical Trials as Topic
MH  - Denmark/epidemiology
MH  - Diuretics/therapeutic use
MH  - Female
MH  - Heart Failure/*drug therapy/mortality
MH  - Humans
MH  - Life Tables
MH  - Male
MH  - Middle Aged
MH  - Mineralocorticoid Receptor Antagonists/therapeutic use
MH  - Phenethylamines/therapeutic use
MH  - Placebos
MH  - Spironolactone/therapeutic use
MH  - Sulfonamides/therapeutic use
MH  - United States
EDAT- 2005/08/18 09:00
MHDA- 2005/09/16 09:00
CRDT- 2005/08/18 09:00
PHST- 2005/08/18 09:00 [pubmed]
PHST- 2005/09/16 09:00 [medline]
PHST- 2005/08/18 09:00 [entrez]
PST - ppublish
SO  - J Insur Med. 2000;32(4):254-61.